Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin

Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) is a potent antidiabetic agent with cardiorenal and weight-losing benefits in patients with type 2 diabetes (T2D). The combination of GLP-1 RA with basal insulin has been suggested in several clinical studies as a useful treatment for intensifying...

Full description

Bibliographic Details
Main Authors:	Hsuan-Wen Chou, Kai-Pi Cheng, An-Chi Lin, Hao-Chang Hung, Ching-Han Lin, Chih-Chen Wang, Hung-Tsung Wu, Horng-Yih Ou
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Pharmaceuticals
Subjects:	diabetes Glucagon-like peptide 1 receptor agonists glycemic control insulin real world study
Online Access:	https://www.mdpi.com/1424-8247/15/12/1569

Similar Items

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
by: Yumie Takeshita, et al.
Published: (2022-06-01)

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
by: Xinrui Tan, et al.
Published: (2023-03-01)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
by: Lee J, et al.
Published: (2019-12-01)

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
by: Agnieszka Jakubowska, et al.
Published: (2024-02-01)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017-03-01)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
by: Takaaki Murakami, et al.
Published: (2020-11-01)

Efficacy of once‐daily glucagon‐like peptide‐1 receptor agonist lixisenatide as an add‐on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual‐level pooled analysis of phase III studies
by: Fuqiang Liu, et al.
Published: (2021-08-01)

Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis
by: Fatima H, et al.
Published: (2023-11-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
by: Won-Young Lee
Published: (2017-02-01)

Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis
by: Yoon Ji Kim, et al.
Published: (2020-08-01)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
by: Vijaya Subramanian, et al.
Published: (2022-09-01)

Glucagon-like peptide-1 receptor agonists, selection within the class. The rational combination of insulin glargine 100 + lixisenatide
by: M. V. Martjanova, et al.
Published: (2020-05-01)

Histologic distribution of insulin and glucagon receptors
by: M. Watanabe, et al.
Published: (1998-02-01)

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy
by: Toshiko Kobori, et al.
Published: (2023-06-01)

Hepatic glucagon receptors expression in response to glucose, insulin, glucagon and immune challenge in grass carp (Ctenophcuyngodon idellus)
by: Chaobin Qin, et al.
Published: (2020-11-01)

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity
by: Jiska van Schaik, et al.
Published: (2020-08-01)

Relationship between Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Disease in Chronic Respiratory Disease and Diabetes
by: Jun-Jun Yeh, et al.
Published: (2024-02-01)

Modulation of Hepatic Insulin and Glucagon Signaling by Nutritional Factors in Broiler Chicken
by: Janka Petrilla, et al.
Published: (2022-02-01)

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
by: Wang W, et al.
Published: (2023-02-01)

Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study
by: Joana Freitas, et al.
Published: (2024-04-01)

Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy
by: Chunyan Liu, et al.
Published: (2024-01-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024-01-01)

Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study
by: Wen-Hsuan Tsai, et al.
Published: (2022-02-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2018-12-01)

Corrigendum: Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-Like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study
by: Wen-Hsuan Tsai, et al.
Published: (2022-03-01)

Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
by: Zeyu Xie, et al.
Published: (2023-08-01)

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
by: Bruno Vergès, et al.
Published: (2022-11-01)

The relationship between insulin and glucagon concentrations in non‐diabetic humans
by: Marcello C. Laurenti, et al.
Published: (2022-07-01)

Obesity, heart failure with preserved ejection fraction, and the role of glucagon‐like peptide‐1 receptor agonists
by: Giuliana Cimino, et al.
Published: (2024-04-01)

Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study
by: Zi-Yang Peng, et al.
Published: (2023-10-01)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
by: Ren Q, et al.
Published: (2022-10-01)

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
by: Giuseppe Lisco, et al.
Published: (2023-10-01)

Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists
by: Qinchao Wu, et al.
Published: (2022-09-01)

EXPRESSION OF INSULIN, GLUCAGON, SOMATOSTATIN, AND PANCREATIC POLYPEPTIDE IN THE PANCREAS OF THE EURASIAN MOORHEN (Gallinula chloropus)
by: Ahmed Abdellatif
Published: (2023-07-01)

Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement
by: Giorgino F, et al.
Published: (2018-05-01)

A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment
by: Chooi Yeng Lee
Published: (2021-09-01)

Glucagon-like Peptide-1 Receptor Activation Reduces Pulmonary Vein Arrhythmogenesis and Regulates Calcium Homeostasis
by: Chao-Shun Chan, et al.
Published: (2023-08-01)